Princeton, NJ – October 12th, 2021
KYBORA is pleased to announce that Howard Lei (MBA, MS-IT, PMP) has joined its team as Senior Advisor, responsible for expanding KYBORA’s operations in China (Shanghai).
Howard is an experienced pharmaceutical executive with over 20 years of consulting and industry experience in China and the US with companies such as ChinaMed Capital, Baiyu Pharma, Digital China Health, IQVIA, PWC, Deloitte, and IBM.
In his career, Howard has led large engagements focused on developing commercial strategies, assessing pricing and market access, running commercial due diligence processes, developing business plans, raising capital, and establishing business partnerships for Chinese and foreign companies. Over the year he has developed an exceptional understanding of the Chinese pharmaceutical landscape, including its key actors, regulations, and market conditions.
“I am very pleased that Howard is joining KYBORA in anticipation of the opening of our Chinese affiliate expected early next year,” said Alan Vanderborght, CEO of KYBORA. “His knowledge of the market and his track record of working with foreign firms position KYBORA as the advisors of choice for all partnering efforts associated with China.” I look forward to working with him to rapidly grow our presence in China and the larger APAC region.”
Howard has an MBA and an MS in IT from the University of Texas. He also has a BS in International Business from the Chinese Culture University in Taipei (Taiwan).
